Figure 2From: Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerProgression-free survival curve. Kaplan-Meier curve showing progression-free survival in patients with metastatic triple-negative breast cancer who were treated with everolimus and carboplatin. The median PFS time was 3 months (95% CI 1 · 6, 4 · 6 months).Back to article page